

Summary Public Assessment Report

Tadalafil Bluefish (tadalafil)

SE/H/2594/01/DC

Summary Public Assessment Report

Tadalafil Bluefish
tadalafil

Film-coated tablet, 20 mg

This is a summary of the public assessment report (PAR) for Tadalafil Bluefish. It explains how the assessment was made and why the authorisation was recommended as well as the conditions of use. It is not intended to provide practical advice on how to use the product.

For practical information about the use of the product, patients should read the package leaflet or contact their doctor or pharmacist.

What is Tadalafil Bluefish and what is it used for?

The product is a 'generic medicine'. This means that it is similar to a 'reference medicine' already authorised in the European Union (EU) called Adcirca.

The product is used in the treatment of pulmonary arterial hypertension in adults and in children aged 2 years and above.

How does Tadalafil Bluefish work?

The product belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors which work by helping the blood vessels around your lungs relax, improving the flow of blood into your lungs. The result of this is an improved ability to do physical activity.

How is Tadalafil Bluefish used?

The pharmaceutical form is film-coated tablet for oral use.

Please read section 3 of the package leaflet for detailed information on dosing recommendations, the route of administration, and the duration of treatment.

The medicine can only be obtained with a prescription in Sweden.

What benefits of Tadalafil Bluefish have been shown in studies?

Because the product is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Adcirca. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

What are the possible side effects from Tadalafil Bluefish?

Because the product is a generic medicine, its benefits and possible side effects are taken as being the same as the reference medicine.

For the full list of side effects, see section 4 of the package leaflet.

For the full list of restrictions, see the package leaflet.

Why is Tadalafil Bluefish approved?

It was concluded that, in accordance with EU requirements, the product has been shown to have comparable quality and is considered to be bioequivalent to the reference medicine. Therefore, the Swedish Medical Products Agency decided that, as for Adcirca, the benefits are greater than its risks and recommended that it can be approved for use.

What measures are being taken to ensure the safe and effective use of Tadalafil Bluefish?

A risk management plan has been developed to ensure that the product is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet, including the appropriate precautions to be followed by healthcare professionals and patients.

Known side effects are continuously monitored. Furthermore, new safety signals reported by patients/healthcare professionals will be monitored/reviewed continuously as well.

Other information about Tadalafil Bluefish

The full PAR for Tadalafil Bluefish can be found on the following website: [MRI - Home](#). For more information about treatment with Tadalafil Bluefish, please read the package leaflet or contact your doctor or pharmacist.

This summary was last updated in 2025-04.